Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 14;9(6):ofac181.
doi: 10.1093/ofid/ofac181. eCollection 2022 Jun.

Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C

Nicolas Nagot  1 , Morgana D'Ottavi  1 , Catherine Quillet  1 , Anne Debellefontaine  1 , Joëlle Castellani  1 , Nicolas Langendorfer  2 , Bertrand Hanslik  2 , Sylvain Guichard  3 , René Baglioni  2 , Vincent Faucherre  2 , Edouard Tuaillon  1 , Georges-Philippe Pageaux  4 , Didier Laureillard  1 , Hélène Donnadieu-Rigole  1
Affiliations

Reaching Hard-to-Reach People Who Use Drugs: A Community-Based Strategy for the Elimination of Hepatitis C

Nicolas Nagot et al. Open Forum Infect Dis. .

Abstract

Background: Elimination of hepatitis C virus (HCV) among people who use drugs (PWUD) remains a challenge even in countries in which HCV care is provided free of cost. We assessed whether an innovative community-based, respondent-driven sampling (RDS) survey, coupled with HCV screening and immediate treatment, could be efficient to detect and cure current PWUD with chronic HCV in a large city of Southern France.

Methods: At a community site with peers, PWUD (cannabis not included) were enrolled after confirmation by a urine drug test. Participants were then screened for hepatitis B virus, HCV, and human immunodeficiency virus and benefited from onsite HCV treatment evaluation and prescription. Peer support was provided during treatment, and a systematic visit was scheduled 12 weeks after the end of treatment. The cost of the intervention was estimated.

Results: Five hundred fifty-four participants were enrolled. Most were male (78.8%) with a median age of 39 years (interquartile range, 33-46). Cocaine (73.1%) and heroine (46.8%) were the main drugs consumed. Overall, 32.6% of PWUD (N = 181) were HCV seropositive, 49 (27.1%) of which had detectable HCV ribonucleic acid and were thus eligible for treatment. Ten of these patients had severe fibrosis. Hepatitis C virus treatment was initiated for 37 (75.5%) patients, 30 (81.1%) of whom completed their treatment and 27 (73.0%) achieved sustained viral response at week 12. The total cost was 161 euros € per screened patient and 1816€ per patient needing treatment.

Conclusions: A community-based RDS survey approach, involving peers, proved efficient and cost-effective to reach and cure PWUD for HCV. This innovative strategy could be key for the final step of HCV elimination. Clinical trial registration. ClinicalTrials.gov, NCT04008927.

Keywords: Costs and cost analysis; drug users; hepatitis C; intervention; mass screening.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Recruitment rate per week of respondent-driven sampling survey, September 15, 2020 to November 27, 2020.
Figure 2.
Figure 2.
Participants flow chart. Abbreviations: AME, Aide médicale de l'Etat (Medical financial assistance from the government); HCV, hepatitis C virus; RDS, respondent-driven sampling; RNA, ribonucleic acid.
See this image and copyright information in PMC

References

    1. Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018; 18:79. - PMC - PubMed
    1. Trickey A, Fraser H, Lim AG, et al. . The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol 2019; 4:435–44. - PMC - PubMed
    1. European Monitoring Centre for Drugs and Drug Addiction . European drug report 2019: trends and developments. Available at: https://data.europa.eu/doi/10.2810/191370. Accessed 28 August 2021. - DOI
    1. Nelson PK, Mathers BM, Cowie B, et al. . Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571–83. - PMC - PubMed
    1. Wiessing L, Ferri M, Grady B, et al. . Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014; 9:e103345. - PMC - PubMed

Associated data